Home › Research › Risk factors
Biomarker-guided clustering of Alzheimer's disease clinical syndromes
Nicola Toschi, Simone Lista, Filippo Baldacci, Enrica Cavedo, Henrik Zetterberg, Kaj Blennow, Ingo Kilimann, Stefan Johannes Teipel et al.. Neurobiology of Aging, 2019-09-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinical to mild cognitive impairment until dementia is driven by interacting genetic/biological mechanisms not fully captured by current clinical/research criteria. We characterized the heterogeneous “construct” of AD through a cerebrospinal fluid biomarker-guided stratification approach. We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (Aβ1-42, t-tau, p-tau181, NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 ± 10.4, 70.4 ± 7.7, 71.7 ± 8.4, 76.2 ± 3.5 years [mean ± SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters. We found 5 distinct clusters (sizes: N = 38, 16, 24, 14, and 21) whose composition was independent of phenotypical groups. Two clusters showed biomarker profiles linked to neurodegenerative processes not associated with classical AD-related pathophysiology. One cluster was characterized by the neuroinflammation biomarker YKL-40. Combining nonlinear data aggregation with informative biomarkers can generate novel patient strata which are representative of cellular/molecular pathophysiology and may aid in predicting disease evolution and mechanistic drug response.
What this study adds
Evidence grade: Low
The record lists 20 participants. In 113 participants, five distinct clusters were found based on cerebrospinal fluid biomarkers, and these clusters did not match the participants' clinical groups. Two clusters showed patterns of neurodegeneration not linked to classical Alzheimer's pathophysiology, and one was characterized by the neuroinflammation biomarker YKL-40.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Toschi, N., Lista, S., Baldacci, F., Cavedo, E., Zetterberg, H., Blennow, K., et al. (2019). Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2019.08.032
Vancouver
Toschi N, Lista S, Baldacci F, Cavedo E, Zetterberg H, Blennow K, et al. Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging. 2019. doi:10.1016/j.neurobiolaging.2019.08.032. PMID: 31585366.
BibTeX
@article{toschi2019-31585366,
author = {Toschi, Nicola and Lista, Simone and Baldacci, Filippo and Cavedo, Enrica and Zetterberg, Henrik and Blennow, Kaj and Kilimann, Ingo and Teipel, Stefan Johannes and others},
title = {{Biomarker-guided clustering of Alzheimer's disease clinical syndromes}},
journal = {Neurobiology of Aging},
year = {2019},
doi = {10.1016/j.neurobiolaging.2019.08.032},
pmid = {31585366},
url = {https://doi.org/10.1016/j.neurobiolaging.2019.08.032}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We found 5 distinct clusters (sizes: N = 38, 16, 24, 14, and 21) whose composition was independent of phenotypical groups.
- Two clusters showed biomarker profiles linked to neurodegenerative processes not associated with classical AD-related pathophysiology.
Why it matters
In 113 participants, five distinct clusters were found based on cerebrospinal fluid biomarkers, and these clusters did not match the participants' clinical groups. Two clusters showed patterns of neurodegeneration not linked to classical Alzheimer's pathophysiology, and one was characterized by the neuroinflammation biomarker YKL-40. This biomarker-guided grouping may help identify patient subgroups, but it does not yet show any treatment, cure, or prevention effect.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants20
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurobiology of Aging) |
| Journal's citation record | 3 / 4 | Neurobiology of Aging: journal h-index 263 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 20 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 52 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.8 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 3 / 6 | Cited 6.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Nadjia Younsi: h-index 6 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 21 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31585366) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neurobiolaging.2019.08.032
- PubMed: 31585366
- Original source →
- Free full text: Neurobiology of Aging →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Risk factors from nearby years
Also in Risk factors
395 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.